Aspirin enhances platelet isoprostanes in type 2 diabetes

Aspirin enhances platelet isoprostanes in type 2 diabetes
For patients with type 2 diabetes mellitus who are treated with aspirin, isoprostanes are overproduced, which is linked with enhanced platelet recruitment, according to a study published online March 16 in Diabetes.

(HealthDay) -- For patients with type 2 diabetes mellitus (T2DM) who are treated with aspirin, isoprostanes are overproduced, which is linked with enhanced platelet recruitment, according to a study published online March 16 in Diabetes.

Noting that aspirin has a modest influence on in T2DM, Roberto Cangemi, M.D., Ph.D., from the Sapienza University of Rome, and colleagues investigated the effect of aspirin on platelet isoprostanes in patients with T2DM. Fifty aspirin-treated and 50 untreated T2DM patients were compared with 100 patients without diabetes, matched for age, gender, atherosclerosis , and aspirin treatment. In 36 aspirin-free patients, with and without diabetes, a seven-day treatment with aspirin was performed.

The researchers found that in patients with diabetes versus those without, and in aspirin-treated versus untreated , higher platelet recruitment, platelet isoprostane, and activation of the catalytic subunit of reduced NAD phosphate oxidase (NOX2) were seen. In all aspirin-treated patients, platelet thromboxane (Tx) A2 was inhibited. In those with and without diabetes, aspirin inhibited platelet TxA2 similarly in the interventional study. A parallel increase was seen in platelet recruitment, isoprostane levels, and NOX2 activation in patients with diabetes, whereas no change was seen in those without diabetes.

"We provide evidence that, in T2DM patients, low-dose aspirin enhances platelet isoprostanes as a consequence of NOX2-generated reactive oxidant species upregulation," the authors write. "This effect mitigates the antiplatelet effect of aspirin and may account for its lower clinical efficacy in T2DM compared with other atherosclerotic settings."


Explore further

Half of patients undergoing cerebrovascular stent placement respond poorly to clopidogrel

More information: Abstract
Full Text (subscription or payment may be required)

Copyright © 2012 HealthDay. All rights reserved.

Citation: Aspirin enhances platelet isoprostanes in type 2 diabetes (2012, March 23) retrieved 4 April 2020 from https://medicalxpress.com/news/2012-03-aspirin-platelet-isoprostanes-diabetes.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments